COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04397562

Not reported

Not reported

2020-05-21

Completed

RCT

Randomized

Adaptive

Blind label

multi-center

Treatment

inclusion criteria: signed informed consent (subject; legally authorized representative) or signed conclusion of panel of independent medical doctors males and non-pregnant females aged 18 years or older at the ic date positive test for sars-cov2 nucleic acid (rna) at the ic date admitted as inpatient to a hospital with radiologically confirmed pneumonia severe form of covid-19. subjects meeting any of the following criteria: total respiratory rate > 30 breaths per minute spo2 ≤ 93% pao2 /fio2 ≤ 300 mmhg chest imaging (x-ray, ct, us) showed lesion progression within 24-48 hours >50% decrease of consciousness level, psychomotor agitation/irritability hemodynamically unstable (systolic blood pressure <90 mmhg or diastolic blood pressure < 60 mmhg or urine output < 20 ml/h) arterial lactate > 2 mmol/l qsofa (quick sequential organ failure assessment score) > 2. subjects meeting three following criteria: low blood pressure (sbp ≤ 100 mmhg); high respiratory rate (≥ 22 breaths/min); altered mentation (glasgow coma scale ≤ 14)

critical covid-19. subjects meeting any of the following: respiratory failure and requiring invasive mechanical ventilation (tracheal intubation) septic shock multiple organ failure life expectancy < 24h, in the opinion of the investigator, unlikely to remain at the investigational site beyond 48 hours use of other monoclonal antibodies for covid-19 treatment current treatment with immunosuppressive agents (including corticosteroids) participating in other drug clinical trials at the ic date or within 60 days after randomization (participation in covid-19 anti-viral trials may be permitted if approved by sponsor) laboratory values: alt / ast > 10 uln at screening platelets < 50х109/l at screening absolute neutrophil count < 1х109/l at screening suspected active bacterial, fungal, viral, or other infection (besides covid-19) confirmed active tuberculosis history of allergic reaction to monoclonal antibodies pregnancy or breastfeeding any illness or laboratory findings that, in the opinion of the study investigator, might pose an additional risk to the patient by their participation in the study,

2

Biocad

18

None

Russia

Severe disease at enrollment

6: Severe disease at enrollment

206

Proportion of patients with sustained clinical recovery

None

Phase 3

[{"arm_notes": "", "treatment_id": 730, "treatment_name": "Levilimab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]